We speculate that inhibition of ERK3/MK5 signaling, which could be achieved by specific inhibitors, might represent an attractive strategy to ameliorate diabetes and obesity (Fig. 7H). Here, MAPKAPK5 is linked to obesity due to melanocortin 4 receptor deficiency.